Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?

The approval of sorafenib and active development of many other molecularly targeted agents in hepatocellular carcinoma (HCC) have presented a challenge to understand the mechanism of action of sorafenib and identify predictive biomarkers to select patients more likely to benefit from sorafenib. The...

Descripción completa

Detalles Bibliográficos
Autor principal: Zhu, Andrew X
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749039/
https://www.ncbi.nlm.nih.gov/pubmed/19703270
http://dx.doi.org/10.1186/1741-7015-7-42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749039/
https://www.ncbi.nlm.nih.gov/pubmed/19703270
http://dx.doi.org/10.1186/1741-7015-7-42

Ejemplares similares